KKKilian L. Kleemann

Kilian L. Kleemann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kilian L. Kleemann has a total of 178 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mitochondria-derived extracellular vesicles mediate Alzheimer’s disease pathology through transmitting microglial Ggt1

    by Yun Li, Xiaohuan Xia, Yiyan Sun, Kailing Jia, Ping Yuan, Rumeng Wei, Zhanping Liang, Meng Shi, Congcong Li, Kilian Kleemann, et al.

    Extracellular vesicles (EVs) can modify pathological progression in Alzheimer’s disease (AD), the most common neurodegenerative disease in older adults, by spreading pathogenic factors. However, the function of mitovesicles (mtVs)—a recently identified subset of EVs—in AD remain unknown. Here we show that release of mtVs is enriched in brain tissue from patients with AD and 5×FAD mice. Administration of 5×FAD mouse brain-derived mtVs (ADmtVs) induced AD-like behavioral and pathological changes in wild-type mice and accelerated disease progression of AD mice. Moreover, the release of mtVs was regulated by mitochondrial respiratory metabolism, and blocking the release of mtVs significantly alleviated AD-like phenotypes. Proteomic analysis identified Ggt1 as a highly enriched protein in ADmtVs. Inhibiting Ggt1 expression and activity mitigated AD-like phenotypes of 5×FAD mice and delayed ADmtV-induced disease progression, suggesting Ggt1 as a pathological cargo of ADmtVs. Our findings highlight the pathological roles of mtVs in AD and highlight mtVs and Ggt1 as potential therapeutic targets.

  • Open Access

    Lysosomal dysfunction drives a transcriptional and epigenetic signature found in disease-associated microglia in neurodegenerative diseases

    by Christopher D. Balak, Johannes C.M. Schlachetzki, Addison J. Lana, Elizabeth West, Christine Hong, Jordan DuGal, Yi Zhou, Benjamin Li, Nathanael J. Spann, Payam Saisan, et al.


  • Open Access

    Trem2 Signaling Exploits Combinatorial Binding of MITF/TFE and ATF/AP-1 Transcription Factors to Drive Disease-Responsive Microglia Phenotypes

    by Johannes Cm Schlachetzki, Dan Zhang, Jean Paul Chadarevian, Nathanael J. Spann, Pik Ki Lau, Kilian L. Kleemann, Xiaoming Zhang, Roisin McManus, Fatir Qureshi, Olivia Corradin, et al.

    Many lines of evidence support protective and pathogenic roles of microglia in Alzheimer’s Disease. Microglia associated with amyloid plaques are proposed to acquire a disease-responsive phenotype through sequential Trem2-independent and Trem2-dependent stages. However, the transcriptional mechanisms driving this transition have not been resolved. Here, we intersect the amyloid-responsive epigenomic landscapes of mouse and human microglia with transcriptional and epigenetic responses of macrophages to an in vivo model of sterile inflammation. We provide evidence for a general model in which activation of a common set of regulators, including members of the MITF/TFE and ATF/AP-1 transcription factor families, is required for both Trem2-independent and Trem2-dependent gene expression. Rather than engaging additional transcription factors, Trem2-dependent gene expression results from boosting the activities of selective enhancers that are initially activated during the Trem2-independent stage and are co-bound by MITF/TFE and ATF/AP-1 factors. These findings reveal transcriptional circuitry required for acquisition of disease-responsive microglia phenotypes.


  • Immune dysfunction in Alzheimer disease

    by Oleg Butovsky, Neta Rosenzweig, Kilian L. Kleemann, Mehdi Jorfi, Vijay K. Kuchroo, Rudolph E. Tanzi, Howard L. Weiner

    Emerging evidence highlights the crucial role of peripheral immune cells in maintaining brain homeostasis and their influence on the pathology of Alzheimer disease (AD). Genome-wide association studies have identified numerous AD risk variants in genes expressed by immune cells, implicating innate and adaptive immune pathways in disease progression. Advances in neuroimmunology have revealed that immune cell crosstalk involving T cells, B cells, monocytes and/or macrophages and neutrophils can modulate the hallmark features of AD, including amyloid plaque accumulation, tau pathology and chronic neuroinflammation. Mechanistic insights suggest that chronic peripheral inflammation, immune exhaustion, metabolic dysfunction and epigenetic reprogramming exacerbate neurodegeneration in AD by promoting toxic inflammation and impairing protein clearance in the brain. These findings may catalyse the development of novel immunomodulatory strategies, such as immune checkpoint inhibition and cytokine targeting, among others, for AD. This Review examines peripheral immune alterations in AD, evaluates related therapeutic opportunities and highlights key knowledge gaps, particularly the need for human-derived data to advance translational progress. Future research should prioritize personalized approaches that integrate genetic risk, immune profiling and ageing to inform next-generation therapies for AD.


  • Top Cited Papers

    Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease

    by Kimitoshi Kimura, Ayshwarya Subramanian, Zhuoran Yin, Ahad Khalilnezhad, Yufan Wu, Danyang He, Karen O. Dixon, Udbhav Kasyap Chitta, Xiaokai Ding, Niraj Adhikari, et al.

    Microglia are the resident immune cells in the brain and have pivotal roles in neurodevelopment and neuroinflammation1,2. This study investigates the function of the immune-checkpoint molecule TIM-3 (encoded by HAVCR2) in microglia. TIM-3 was recently identified as a genetic risk factor for late-onset Alzheimer’s disease3, and it can induce T cell exhaustion4. However, its specific function in brain microglia remains unclear. We demonstrate in mouse models that TGFβ signalling induces TIM-3 expression in microglia. In turn, TIM-3 interacts with SMAD2 and TGFBR2 through its carboxy-terminal tail, which enhances TGFβ signalling by promoting TGFBR-mediated SMAD2 phosphorylation, and this process maintains microglial homeostasis. Genetic deletion of Havcr2 in microglia leads to increased phagocytic activity and a gene-expression profile consistent with the neurodegenerative microglial phenotype (MGnD), also referred to as disease-associated microglia (DAM). Furthermore, microglia-targeted deletion of Havcr2 ameliorates cognitive impairment and reduces amyloid-β pathology in 5×FAD mice (a transgenic model of Alzheimer’s disease). Single-nucleus RNA sequencing revealed a subpopulation of MGnD microglia in Havcr2-deficient 5×FAD mice characterized by increased pro-phagocytic and anti-inflammatory gene expression alongside reduced pro-inflammatory gene expression. These transcriptomic changes were corroborated by single-cell RNA sequencing data across most microglial clusters in Havcr2-deficient 5×FAD mice. Our findings reveal that TIM-3 mediates microglia homeostasis through TGFβ signalling and highlight the therapeutic potential of targeting microglial TIM-3 in Alzheimer’s disease.


  • Open Access

    Radial glia integrin avb8 regulates cell autonomous microglial TGFβ1 signaling that is necessary for microglial identity

    by Gabriel L. McKinsey, Nicolas Santander, Xiaoming Zhang, Kilian L. Kleemann, Lauren Tran, Aditya Katewa, Kaylynn Conant, Matthew Barraza, Kian Waddell, Carlos O. Lizama, et al.

    Microglial diversity arises from the interplay between inherent genetic programs and external environmental signals. However, the mechanisms by which these processes develop and interact within the growing brain are not yet fully understood. Here, we show that radial glia-expressed integrin beta 8 (ITGB8) activates microglia-expressed TGFβ1 to drive microglial development. Domain-restricted deletion of Itgb8 in these progenitors results in regionally restricted and developmentally arrested microglia that persist into adulthood. In the absence of autocrine TGFβ1 signaling, microglia adopt a similar phenotype, leading to neuromotor symptoms almost identical to Itgb8 mutant mice. In contrast, microglia lacking the canonical TGFβ signal transducers Smad2 and Smad3 have a less polarized dysmature phenotype and correspondingly less severe neuromotor dysfunction. Our study describes the spatio-temporal regulation of TGFβ activation and signaling in the brain necessary to promote microglial development, and provides evidence for the adoption of microglial developmental signaling pathways in brain injury or disease.


  • Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy

    by Wesley Brandao, Nimansha Jain, Zhuoran Yin, Kilian L. Kleemann, Madison Carpenter, Xin Bao, Javier R. Serrano, Eric Tycksen, Ana Durao, Jen-Li Barry, et al.

    Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder. Antiamyloid antibody treatments modestly slow disease progression in mild dementia due to AD. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays an important role in disease onset and progression. Thus, a major question is how to modulate the phenotype and function of microglia to treat AD. Xenon (Xe) gas is a noble gas used in human patients as an anesthetic and a neuroprotectant used for treating brain injuries. Xe penetrates the blood-brain barrier, which could make it an effective therapeutic. To assess the effect of Xe on microglia and AD pathology, we designed a custom Xe inhalation chamber and treated several mouse models of AD with Xe gas. Xe treatment induced mouse microglia to adopt an intermediate activation state that we have termed pre–neurodegenerative microglia (pre-MGnD). This microglial phenotypic transition was observed in mouse models of acute neurodegeneration and amyloidosis (APP/PS1 and 5xFAD mice) and tauopathy (P301S mice). This microglial state enhanced amyloid plaque compaction and reduced dystrophic neurites in the APP/PS1 and 5xFAD mouse models. Moreover, Xe inhalation reduced brain atrophy and neuroinflammation and improved nest-building behavior in P301S mice. Mechanistically, Xe inhalation induced homeostatic brain microglia toward a pre-MGnD state through IFN-γ signaling that maintained the microglial phagocytic response in APP/PS1 and 5xFAD mice while suppressing the microglial proinflammatory phenotype in P301S mice. These results support the translation of Xe inhalation as an approach for treating AD.


  • Open Access

    APOE4 impairs microglia‐astrocyte response in Alzheimer’s disease by inducing TGFβ‐mediated checkpoints

    by Oleg Butovsky, Zhuoran Yin, Neta Rosenzweig, Kilian Kleemann, Xiaoming Zhang, Wesley N Brandao, Milica Margeta, Caitlin M Schroeder, Sebastian Silveira, Christian Gauthier, et al.

    Background: APOE ε4 is the strongest genetic risk factor for late‐onset Alzheimer’s disease (AD). The contribution of microglial APOE4 to AD pathogenesis is unknown, although APOE has the most enriched gene expression in neurodegenerative microglia (MGnD).Method: Generation of CX3CR1‐CREERT2 mice crossed to APOE‐KI(E3 and E4)fl/fl: APP/PS1 and APOE‐KI(E3 and E4)fl/fl: P301S mice. Microglia and astrocytes were isolated and sequenced using either bulk RNA‐seq (MGnD‐Paradigm) or single‐cell RNA‐seq. Crosstalk between cells was determined using the NichenetR database and validated using 1) recombinant Lgals3 intracranial injection into APP/PS1 mice and 2) adoptive transfer of microglia, from APOE3‐KI, APOE4‐KI, and APOE4‐cKO mice challenged with labeled apoptotic neurons, into WT mice and isolation of astrocytes. Validation in the brain of AD donors carrying the APOE e3/3 and e3/4 alleles.Result: Here we show, in mice and in humans, a negative role of microglial APOE4 in the induction of MGnD response to neurodegeneration. Deletion of microglial APOE4 restores MGnD phenotype, associated with neuroprotection in P301S tau transgenic mice, and decreases pathology in APP/PS1 mice. MGnD‐astrocyte crosstalk associated with b‐amyloid (Ab) plaque encapsulation and clearance is mediated via Lgals3 signaling following microglial APOE4 deletion. In the brain of AD donors carrying the APOE ε4 allele, we found a sex‐dependent reciprocal induction of AD risk factors associated with suppression of MGnD genes in females, including LGALS3, as compared to APOE ε3/3 carriers. Mechanistically, APOE4‐mediated induction of ITGB8‐TGFb signaling impairs MGnD response via upregulation of TGFb‐mediated microglial homeostatic checkpoints, including INPP5D. Microglial deletion of Inpp5d restores MGnD‐astrocyte crosstalk and facilitates plaque clearance in APP/PS1 mice. Genetic and pharmacological blocking of ITGB8‐TGFb signaling enhanced MGnD response associated with increased plaque clearance in AD mice.Conclusion: We identify the microglial APOE4‐ITGB8‐TGFb pathway as a negative regulator of microglia‐astrocyte response to AD pathology, and restoring MGnD phenotype via blocking ITGB8‐TGFb signaling may provide new molecular targets to modulate and restore functional microglia in AD.

  • Open Access

    Xenon gas (Xe) treatment to restore microglial functions in Alzheimer’s disease (AD)

    by Wesley N Brandao, Zhuoran Yin, Kilian Kleemann, Xiaoming Zhang, Neta Rosenzweig, Nimansha Jain, Mathew Blurton Jones, David M. Holtzman, Ilya Ilin, Howard L Weiner, et al.

    Background: Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder. Emerging evidence shows that homeostatic dysregulation of the brain immune system orchestrated by microglia plays a significant role in the onset and progression of the disease. Our aim is to develop a therapy based on Xenon inhalation that addresses 1) penetration through the blood‐brain barrier, 2) microglial modulation, and 3) neuroprotection.Method: Through a special chamber that can control the supply of Xenon gas in a closed‐circuit system, we evaluated the Xenon effect in microglia biology in models of acute and chronic neurodegeneration and humanized AD mice.Result: We found that Xenon‐treatment can directly modulate the microglia phenotype, by increasing their phagocytic response and decreasing their proinflammatory signature. Weekly‐based Xenon inhalation decreased Ab‐plaque load and tauopathy and maintained microglial phenotype in an intermediated state associated with IFNg signaling and lipid biosynthesis signatures. Moreover, Xenon treatment also affects the peripheral immune response with a decrease in B cell and an increase in the tolerogenic signature in myeloid cells, which was validated by scRNAseq and FACS analysis. Importantly, Xenon treatment, directly modulated IPS‐derived microglia (iMGL) in vitro by suppressing their inflammatory signature and inducing lipid biosynthesis. Finally, treatment of humanized 5xFAD mice transplanted with iMGLs reduced Ab plaque load.Conclusion: Xenon treatment modulates microglia and peripheral immune cells phenotype towards a reparative phenotype. This modulation is accompanied by reduction in Ab pathology in both mouse and humanized AD models, showing that Xenon inhalation can be used as a possible treatment for AD.


  • Open Access

    APOE‐4 dependent dysfunctional neutrophil‐microglia crosstalk accelerates Alzheimer’s disease

    by Neta Rosenzweig, Kilian Kleemann, Madeline Grucci, Micheal Aronchik, Oleg Butovsky

    Background: APOE4 is the strongest genetic risk factor for late‐onset Alzheimer’s disease (AD). The role of human APOE variants in AD has been studied extensively in the regulation of brain cells but not in peripheral immunity. APOE is also expressed in neutrophils and controls their activation. Moreover, neutrophils have been shown to play a negative role in AD mice via the induction of neutrophil extracellular traps (NETs)Method: Here we aimed to dissect the impact of APOE4‐neutrophils on AD pathology, using Ly6g‐CRE mice crossed to APOE‐KI(E3 and E4)fl/fl:APP/PS1.Result: We identified a cell intrinsic role of APOE3 in controlling neutrophil maturation and degranulation, which is exacerbated in APOE4‐KI neutrophils and reduced in APOE4‐KO neutrophils. Moreover, APOE4 neutrophils accumulated in the brains of AD mice and in AD patients, associated with microglia at sites of plaque pathology. Here we show that genetic deletion of APOE4 in neutrophils suppressed their activation and reduced their recruitment to the brains of APP/PS1 mice. RNAseq analysis showed increased proportion of disease associated microglia (DAM/MGnD) in APP/PS1: Ly6g‐CRE:APOE4fl/fl mice, associated with reduced plaque pathology. Furthermore, we show impaired induction of MGnD signature in AD brains of APOE4 carriers. Our findings show that APOE4‐induced inflammatory neutrophils are recruited to the diseased brain and impair MGnD response leading to accelerated AD pathology.Conclusion: Taken together, these findings identify a cell‐intrinsic role of APOE4 in the induction of hyperactivated neutrophils recruited to the brain, which may provide new molecular targets to modulate and restore functional microglia in AD.